| Literature DB >> 36120451 |
Asegdew Atlaw1,2, Habtamu Biazin Kebede1, Abdurezak Ahmed Abdela3, Yimtubezinash Woldeamanuel1.
Abstract
Introduction: Infected diabetic foot ulcer (IDFU) is a worldwide problem associated with diabetes mellitus. It could lead from soft tissue infection to bone infection and is a leading cause of lower limb amputation. Gram-negative and Gram-positive bacteria, including anaerobic bacteria and fungi, are considered potential causes of infection. The early diagnosis of DFU infection and appropriate treatment based on the identification of the pathogens and their antimicrobial susceptibility pattern is important for good prognosis. Therefore, the purpose of this study was to isolate the bacteria that infect foot ulcers in selected Hospitals and determine their antimicrobial resistance profile. Method: An institutional-based multicenter, cross-sectional study was conducted in selected Hospitals in Addis Ababa, Ethiopia, from November 2020 to May 2021. A sterile swab was used to collect samples from the foot ulcer and a sterile needle to collect pus. Isolates were identified by culture, Gram-staining, and a series of biochemical tests. For each bacterial species identified, the antibiotic profiling was determined by the Kirby-Bauer disk diffusion method.Entities:
Keywords: addis Ababa; antimicrobial susceptibility testing; diabetic Mellitus; diabetic foot ulcer; ethiopia; multidrug resistance
Mesh:
Substances:
Year: 2022 PMID: 36120451 PMCID: PMC9472130 DOI: 10.3389/fendo.2022.987487
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 6.055
Sociodemographic and clinical characteristics of the study participants.
| Characteristics | Categories | Frequency (n) | (%) |
|---|---|---|---|
| Sex | Male | 89 | 68.2 |
| Female | 41 | 31.8 | |
| Age | <40 | 4 | 3.2 |
| 41 | 36 | 27.2 | |
| 51 | 42 | 32.7 | |
| 61 | 30 | 29.5 | |
| 71-80 | 17 | 14.4 | |
| ≥ 81 | 1 | 0.8 | |
| Total | 130 | 100 | |
| Number of participants | TASH | 23 | 17.69 |
| Yekatit | 31 | 23.84 | |
| Menelik | 76 | 58.46 | |
| Residence | Urban | 110 | 84.61 |
| Rural | 20 | 15.38 | |
| Type of diabetes | Type | 67 | 51.53 |
| Type-II | 63 | 48.46 | |
| Duration of diabetes | < 1 year | 0 | 0 |
| 1 | 75 | 53.38 | |
| 11 | 38 | 27.69 | |
| 21 | 16 | 12.30 | |
| >31 years | 1 | 0.76 | |
| HGBA1C | 1.61 | 0 | 0 |
| 9.67-16.11 mmol/mol | 75 | 57.69 | |
| 17.72 | 43 | 33.07 | |
| ≥24.17 mmol/mol | 2 | 1.53 | |
| Hypertension | Yes | 70 | 53.84 |
| No | 60 | 46.15 | |
| Kidney disease | Yes | 24 | 18.46 |
| No | 106 | 81.53 | |
| Peripheral Neuropathy (PN) | Yes | 104 | 80 |
| No | 26 | 20 | |
| PVD | Yes | 43 | 33.07 |
| No | 87 | 66.92 | |
| Leg skin texture | Dry skin | 40 | 30.76 |
| Moist skin | 53 | 40.7 | |
| Cracked skin | 37 | 28.46 | |
| Wagner | Grade 1 | 3 | 2.3 |
| Grade 2 | 45 | 34.61 | |
| Grade 3 | 62 | 47.69 | |
| Grade 4 | 19 | 14.61 | |
| Grade 5 | 1 | 0.76 | |
|
| 130 | 100 | |
PVD, Peripheral Vascular Disease; HGBA1C, Hemoglobin A1C.
Bacterial isolates among diabetic foot ulcer study participants.
| Bacterial profiles | Frequency | Percentage | |
|---|---|---|---|
|
| Mono | 38 | 31.66 |
| Poly | 82 | 68.33 | |
|
|
| 32 | 25.19 |
|
| 24 | 18.89 | |
|
| 21 | 16.53 | |
|
| 12 | 9.44 | |
|
| 10 | 7.87 | |
| Serratia | 6 | 4.72 | |
|
| 4 | 3.14 | |
|
| 4 | 3.14 | |
|
| 4 | 3.14 | |
|
| 4 | 3.14 | |
|
| 3 | 2.36 | |
|
| 2 | 1.57 | |
|
| 1 | 0.78 | |
| Total isolates | 127 | 100 | |
Distribution of bacterial isolates among Wagner classification of DFUs system.
| Isolated Bacteria | Wagner classification of DFUs, n (%) | Total | ||||
|---|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | ||
|
| 0 | 0 | 10(83.3) | 2 (16.6) | 0 | 12 (9.4) |
|
| 0 | 1 (25) | 2 (50) | 1 (25) | 0 | 4 (3.1) |
|
| 0 | 4 (19) | 9 (42.8) | 7 (33.3) | 1 (4.7) | 21 (16.5) |
|
| 0 | 2 (50) | 2 (50) | 0 | 0 | 4 (3.1) |
|
| 0 | 0 | 0 | 1 | 0 | 1 (0.8) |
|
| 0 | 1 (10) | 5 (50) | 4 (40) | 0 | 10 (7.8) |
|
| 0 | 2 (50) | 1 (25) | 1 (25) | 0 | 4 (3.1) |
|
| 0 | 2 (50) | 0 | 2 (50) | 0 | 4 (3.1) |
|
| 0 | 7 (29.1) | 13(54.1) | 4 (16.6) | 0 | 24 (18.8) |
|
| 1 (3.1) | 11(34.3) | 18(56.2) | 2 (6.25) | 0 | 32 (25.1) |
|
| 1 (50) | 0 | 1 (50) | 0 | 0 | 2 (1.5) |
|
| 0 | 3 (50) | 2 (33.3) | 1 (16.6) | 0 | 6 (4.7) |
|
| 0 | 1(33.3) | 1 (33.3) | 1 (33.3) | 0 | 3 (2.3) |
|
| 2(1.5) | 34(26.7) | 64(50.3) | 26(20.4) | 1(0.8) | 127 (100) |
Antimicrobial susceptibility patterns of isolated gram-positive bacteria.
| Antimicrobial tested | Susceptibility and resistance pattern of isolated Gram-positive bacteria N (%) | |||||||
|---|---|---|---|---|---|---|---|---|
| Classes | Antibiotics |
|
|
|
| |||
| R | S | R | S | S | R | S | ||
| Penicillin | PEN | 32 (100) | 0 | 4 (100) | 0 | 2 (100) | 1 (33.3) | 2 (66.6) |
| OX | 26 (81.2) | 6 (18.7) | 4 (100) | 0 | 2 (100) | 1 (33.3) | 2 (66.6) | |
| Cephamycin | CXT | 26 (81) | 6 (19) | 4 (100) | 0 | 2 (100) | 1 (33.3) | 2 (66.6) |
| Aminoglycosides | GEN | 25 (78) | 7 (22) | 4 (100) | 0 | 2 (100) | 2 (66.6) | 1 (33.3) |
| Aminoglycosides | AMK | 6(18) | 26 (82) | 2 (100) | 2 (50) | – | 0 | 3 (100%) |
| Tetracycline | DO | 26 (81.3) | 6 (18.7) | 4 (100) | 0 | – | 2 (66.6) | 1 (33.3) |
| Quinolones | CPR | 16 (50) | 16 (50) | 3 (75) | 1 (25) | 2 (100) | 1 (33) | 2 (67) |
| Bacitracin | BC | 32 (100) | 0 | 4 (100) | 0 | 2 (100) | 3 (100) | 0 |
| Sulfonamides | SXT | 21 (87.5) | 3 (12.5) | 3 (75) | 1 (25) | 2 (100) | 0 | 3 (100) |
| Chloramphenicol | CHL | 0 | 32 (100) | 0 | 4(100) | 2 (100) | 0 | 3 (100) |
| Macrolides | ER | 22 (68.8) | 10 (31.2) | 4 (100) | 0 | 2(100) | 0 | 3(100) |
| DA | 12 38) | 20 (62) | 3 (75) | 1 (25) | 2 (100) | 0 | 3 (100) | |
| Glycopeptide | VA | 12 (37) | 20 (63) | 2 (50) | 2 (50) | 2 (100) | 0 | 3 (100) |
| Total | 198 (56.6) | 152 (43.4) | 41 (78.8) | 11 (21.2) | 22 (100) | 11 (28.2) | 28 (71.8) | |
Keys: PEN, Penicillin; OX, Oxacillin; CXT, Cefoxitin; GEN, Gentamycin; AMK, Amikacin; DO, Doxycycline; CPR, Ciprofloxacin; BC, Bacitracin; SXT, TTrime; CHL, Chloramphenicol; ER, Erythromycin; DA, Clindamycin; VA, Vancomycin.
Resistance pattern of gram-negative isolates.
| Antibiotic tested | Resistance pattern of isolated Gram-negative bacteria n (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Classes | Antibiotics |
|
|
|
| Serratia(N = 6) |
|
|
|
| Aminoglycosides | AMK | 10 (83.3) | 11 (45.8) | 5 (50 | 5 (28.8) | 2(33.3) | 2 (50) | 2 (50) | 0 |
| TOB | 12 (83.3) | 21 (87.5) | 7 (70) | 19 (90.5 | 5 (83.3) | 4 (100) | 3 (75) | 3 (75) | |
| Tetracycline | DO | 11 (91.7) | 23 (95.8) | 10 (100) | 18 (86) | 6 (100) | 4 (100) | 3 (75) | 3 (75) |
| Quinolones | CPR | 8 (66.7) | 13 (54.2) | 4 (40) | 8 (38.0) | 5(83.3) | 2 (50) | 2 (50) | 2 (50) |
| Sulfonamides | SXT | 10 (83.3) | 21 (87.5) | 9 (90) | 19 (90) | 5(83.3) | 2 (50) | 4 (100) | 4 (100) |
| Chloramphenicol | CHL | 8 (66.7) | 16 (66.7) | 3 (30) | 2 (9.5) | 6(100) | 2 (50) | 0 | 2 (100) |
| Monobactam | ATM | 7 (58.3) | 13 (54.2) | 2 (20) | 5 (28.8) | 2 (33.3) | 2 (50) | 3 (75) | 0 |
| Polymyxin | PB | 12 (100) | 24 (100) | 10 (100) | 21 (100) | 6 (100) | 4 (100) | 4 (100) | 4 (100) |
| Cephalosporins | CXT | 11 (91.6) | 24 (100) | 10 (100) | 20 95.2) | 6(100) | 4(100) | 4(50) | 4(100) |
| CFP | 12 (100) | 24 (100) | 10 (100) | 21 (100) | 6 (100) | 4 (100) | 4 (100) | 4 (100) | |
| CTR | 12 (100) | 20 (83.3) | 6 (60) | 11 (52) | 6 (100) | 3 (75) | 1 (25) | 2 (50) | |
| CTX | 11 (8.3) | 21 (87.5) | 8 (80) | 15 (74) | 6 (100) | 3 (75) | 1 (25) | 3 (75) | |
| CAZ | 7 (58.3) | 13 (54.2) | 4 (40) | 7 (33.3) | 3 (33) | 3 (75) | 0 | 0 | |
| Beta-lactam Inhibitors | TZP | 6 (50) | 16 (66.7) | 4 (40) | 7 (33.3) | 2(33.3) | 2 (50) | 0 | 2 (50) |
| SAM | 12 (100) | 24 (100) | 10 (100) | 21 (100) | 6 (100) | 4 (100) | 4 (100) | 4 (100) | |
| AUG | 12 (100) | 24 (100) | 10 (100) | 21 (100) | 6 (100) | 4 (100) | 4 (100) | 4 (100) | |
| Carbapenem | IMI | 6 (50) | 11 (45.8) | 6 (60) | 5 (23.8) | 4 (66.6) | 1 (25) | 0 | 0 |
| MER | 7 (58.3) | 9 (37.5) | 4(40) | 6 (28.5) | 3 (50) | 1(25) | 1(25) | 0 | |
AMK, Amikacin; TOB, Tobramycin; DO, Doxycycline; CPR, Ciprofloxacin; SXT, Trimethoprim-sulfamethoxazole; FEP, Cefepime; TZP, Piperacillin-Tazobactam; SAM, Ampicillin-Sulbactam; AUG, Augmentin; CTR, Ceftriaxone; CTX, Cefotaxime; CAZ, Ceftazidime; IMI, Imipenem; MER, Meropenem; ATM, Aztreonam.
Antibiogram of bacterial isolates.
| Bacterial isolates | Antibiogram pattern, N (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R0 | R1 | R2 | R3 | R4 | R5 | R6 | R7 | R8 | R9 | R10 | MDR | |
|
| 0 | 1 (3.1) | 3 (9.3) | 4 (12.5) | 8 (25) | 5 (15.6) | 5 (15.6) | 3 (9.3) | 3 (9.3) | 0 | 0 | 28 (87.5) |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (25) | 0 | 3 (75) | 0 | 4 (100) |
|
| 2 (100) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 1 (33.3) | 1 (33.3) | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 3 (100) |
|
| 0 | 0 | 2 (8.3) | 3 (12.5) | 3 (12.5) | 4 (16.6) | 5 (20.8) | 0 | 6 (25) | 1 (4.1) | 0 | 22 (91.6) |
|
| 0 | 0 | 0 | 6 28.5) | 6 (28.5) | 4 (19.0) | 3 (14.2) | 1(4.7) | 1 (4.7) | 0 | 0 | 21 (100) |
|
| 0 | 0 | 0 | 0 | 2 (16.6) | 2 (16.6) | 2 (16.6) | 1(8.3) | 2 (16.6) | 3 (25) | 0 | 12 (100) |
|
| 0 | 0 | 0 | 0 | 2 (20) | 4 (40) | 2 (20) | 0 | 1 (10) | 1 (10) | 0 | 10 (100) |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 4(66.6) | 2 (33.3) | 0 | 0 | 0 | 6 (100) |
|
| 0 | 0 | 0 | 1(25) | 0 | 0 | 2 (50) | 1 (25) | 0 | 0 | 0 | 4 (1000 |
|
| 0 | 0 | 0 | 0 | 2 (50) | 1 (25) | 1 (25) | 0 | 0 | 0 | 0 | 4 (100) |
|
| 0 | 0 | 1 (25) | 1 (25) | 0 | 1 (25) | 1 (25) | 0 | 0 | 0 | 0 | 3 (75) |
|
| 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
|
| 2 (1.6) | 1 (0.7) | 6 (4.72 | 16 (12.5 | 25 (19.6) | 22 (17.3) | 25 (19.6) | 9 (7.08) | 13 (10.2) | 8 (6.2) | 0 | 118 (92.9) |
Sensitive for all classes of antibiotics (R0), Resistance for one class of antibiotics (R1), Resistance for two classes of antibiotics (R2), Resistance for three classes of antibiotics (R3), Resistance for four classes of antibiotics (R4) etc., MDR-Multidrug-resistance.